“…PSA might be affected by prostate volume, the grade and stage of neoplasms, patient age, and ethnicity (Partin et al, 1990). Several studies reported that the extent and grade of inflammation were correlated positively with serum PSA levels (Kandirali et al, 2007;Ozden et al, 2007). We also reported that PSA levels were positively correlated with NLR which confirms the association of inflammation and PSA.…”
Purpose: The aim of this study was to evaluate inflammation parameters and assess the utility of the neutrophillymphocyte ratio (NLR) as a simple and readily available predictor for clinical disease activity in patients with nenign prostate hyperplasia BPH. We also aimed to investigate the relationship between inflammatory parameters with α-blocker therapy response, and evaluate the potential association between NLR and the progression of benign prostatic hyperplasia (BPH). Materials and Methods: We examined 320 consecutive patients ( .001); however, there were no significant differences between the groups in terms of age (p>0.05), and prostate volume (p>0.05). Conclusions: NLR can predict BPH progression. We propose that increased inflammation is negatively associated with clinical status in BPH patients and suggest that NLR can give information along with LUTS severity which may be used as a readikly accessible marker for patient follow-up.
“…PSA might be affected by prostate volume, the grade and stage of neoplasms, patient age, and ethnicity (Partin et al, 1990). Several studies reported that the extent and grade of inflammation were correlated positively with serum PSA levels (Kandirali et al, 2007;Ozden et al, 2007). We also reported that PSA levels were positively correlated with NLR which confirms the association of inflammation and PSA.…”
Purpose: The aim of this study was to evaluate inflammation parameters and assess the utility of the neutrophillymphocyte ratio (NLR) as a simple and readily available predictor for clinical disease activity in patients with nenign prostate hyperplasia BPH. We also aimed to investigate the relationship between inflammatory parameters with α-blocker therapy response, and evaluate the potential association between NLR and the progression of benign prostatic hyperplasia (BPH). Materials and Methods: We examined 320 consecutive patients ( .001); however, there were no significant differences between the groups in terms of age (p>0.05), and prostate volume (p>0.05). Conclusions: NLR can predict BPH progression. We propose that increased inflammation is negatively associated with clinical status in BPH patients and suggest that NLR can give information along with LUTS severity which may be used as a readikly accessible marker for patient follow-up.
“…As reported in several studies, the extent of inflammation and grade correlated positively with the serum PSA level (28,29). Probably in the Group II we have selected patients with lower extension and grade of flogosis: this finding is also supported by the fact that between the two subsets there were no statistical significant differences in terms of total PSA.…”
Objective: To evaluate the efficacy of Profluss® on prostatic chronic inflammation (PCI).
Materials and Methods:We prospectively enrolled 168 subjects affected by LUTS due to bladder outlet obstruction submitted to 12 cores prostatic biopsy for suspected prostate cancer + 2 cores collected for PCI valuation. First group consisted of 108 subjects, with histological diagnosis of PCI associated with BPH and high grade PIN and/or ASAP, randomly assigned to 1:1 ratio to daily Profluss® (group I) for 6 months or to control group (group Ic). Second group consisted of 60 subjects, with histological diagnosis of BPH, randomly assigned to 1:1 ratio to daily Profluss® + α-blockers treatment (group II) for 3 months or to control group (group IIc). After 6 months first group underwent 24 cores prostatic re-biopsy + 2 cores for PCI while after 3 months second group underwent two-cores prostatic for PCI. Specimens were evaluated for changes in inflammation parameters and for density of T-cells (CD3, CD8), B-cells (CD20) and macrophages (CD68). Results: At follow-up there were statistical significant reductions of extension and grading of flogosis, mean values of CD20, CD3, CD68 and mean PSA value in group I compared to Ic, while extension and grading of flogosis in group II were inferior to IIc but not statistical significant. A statistically significant reduction in the density of CD20, CD3, CD68, CD8 was demonstrated in group II in respect to control IIc. Conclusions: Serenoa repens+Selenium+Lycopene may have an anti-inflammatory activity that could be of interest in the treatment of PCI in BPH and/or PIN/ASAP patients.
“…Prostatic inflammation is detected in some biopsy specimens, and subclinical prostatitis is known to cause increases in the serum PSA level (35)(36)(37). Morote et al (13) retrospectively studied 284 patients with no evidence of cancer on sextant ultrasound-guided biopsies.…”
Abstract. Saturation prostate biopsy protocols have been developed to improve the prostate cancer (PCa) detection rate, particularly in the setting of repeat biopsies. The present study attempted to clarify the association between PCa detection and various risk factors in repeat saturation biopsies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.